Q4 2021 reported. Yesterday, BioSig Technologies reported their fourth quarter, missing on top-line expectations, with no unit sales reported. That said, the company continues to roll out a phased commercialization strategy to promote faster revenue growth longer term.Recent hires are expected to move the needle. In December 2021, the company introduced Gray Fleming as Chief Commercial Officer and acquired the services of Access Strategy Partners to assist in relationship management. Just last week, the company introduced John Sieckhaus as Chief Operating Officer. All these filled positions are upgrades or new positions that are expected to produce better revenues.Company cost-cutting. As part of their phased strategy, BioSig Technologies also expects to reduce headcount where BSGM believed there was an inability to convert or promote accounts. Part of the headcount savings has been and will be diverted to better commercial team additions. With the reductions, overhead could be reduced up to 20%.Lowering revenues in the front half of 2022, but believe the groundwork being laid will pay off 2H 2022 and beyond. We are reducing our revenue expectations in the first three quarters of 2022 as the phased effort moves forward but are not changing our long-term expectations.Price Target $4.00. While building out slower than expected, commercialization efforts underway will advance PURE EP as a desirable, if not "must-have" component of electrophysiology labs in the U.S. and abroad. We are keeping our one-year price target at $4.00 as well as our Outperform rating. Our target is based on expected $0.55 2027 EPs, discounted 20% and applying a 20x multiple. Read More >>